Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging

Journal of Neuropathology and Experimental Neurology

Volumn 69, Issue 10, 2010, Pages 1034-1043

  Silverberg, Gerald D ^a   Messier, Arthur A ^a   Miller, Miles C ^a   MacHan, Jason T ^b   Majmudar, Samir S ^a   Stopa, Edward G ^c   Donahue, John E ^c   Johanson, Conrad E ^a  

^a Brown University Program in Neurosurgery   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Aging; Alzheimer disease; Amyloid; Blood brain barrier; LRP 1; P gp; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; GLYCOPROTEIN P; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); CARRIER PROTEIN; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN RECEPTOR; PEPTIDE FRAGMENT; PEPTIDOGLYCAN RECEPTOR;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING; AGE; ANIMAL; BLOOD EYE BARRIER; FISCHER 344 RAT; GENE EXPRESSION REGULATION; METABOLISM; MICROVASCULATURE; PATHOLOGY; PHYSIOLOGY; STATISTICAL MODEL;

AGE FACTORS; AGING; AMYLOID; AMYLOID BETA-PROTEIN; ANIMALS; BLOOD-AQUEOUS BARRIER; GENE EXPRESSION REGULATION; LINEAR MODELS; MALE; MEMBRANE TRANSPORT PROTEINS; MICROVESSELS; P-GLYCOPROTEIN; PEPTIDE FRAGMENTS; RATS; RATS, INBRED F344; RECEPTORS, CELL SURFACE; RECEPTORS, IMMUNOLOGIC;

EID: 77957963537     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181f46e25     Document Type: Article

References (70)

1. Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neu-rochem 2004;89:807-11
2. Rubenstein E. Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet 1998;351:283-85
3. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid A-protein. Ann N Y Acad Sci 2000;924:17-25
4. Silverberg GD, Mayo M, Saul T, et al. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: A hypothesis. Lancet Neurol 2003;2:506-11
5. Donahue JE, Flaherty SL, Johanson CE, et al. RAGE, LRP-1, and amyloid-A protein in Alzheimer's disease. Acta Neuropathol 2006;112: 405-15
6. Miller MC, Tavares R, Johanson CE, et al. Hippocampal RAGE immu-noreactivity in early and advanced Alzheimer's disease. Brain Res 2008; 1230:273-80
7. Qiu WQ, Walsh DM, Ye Z, et al. Insulin-degrading enzyme regulates extracellular levels of amyloid A-protein by degradation. J Biol Chem 1998;273:32730-38
8. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major AA-42Ydegrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000;6:143-50
9. Iwata N, Tsubuki S, Takaki Y, et al. Metabolic regulation of brain AA by neprilysin. Science 2001;292:1550-52
10. Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid A peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003;350:113-16
11. Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid A-peptide from brain: Transport or metabolism? Nat Med. 2000;6:718-19
12. Davson H, Oldendorf WH. Symposium on membrane transport. Transport in the central nervous system. Proc R Soc Med 1967;60:326-29
13. Oldendorf WH, Davson H. Brain extracellular space and the sink action of cerebrospinal fluid. Measurement of rabbit brain extracellular space using sucrose labeled with carbon 14. Arch Neurol 1967;17:196-205
14. Rennels ML, Blaumanis OR, Grady PA. Rapid solute transport throughout the brain via paravascular fluid pathways. Adv Neurol 1990;52:431-39
15. Ghersi-Egea JF, Gorevic PD, Ghiso J, et al. Fate of cerebrospinal fluidY borne amyloid A-peptide: Rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 1996;67:880-83
16. Weller RO. Pathology of cerebrospinal fluid and interstitial fluid of the CNS: Significance for Alzheimer's disease, prion disorders and multiple sclerosis. J Neuropathol Exp Neurol 1998;57:885-94
17. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimer's amyloid-A1-40 peptide from brain by LDL receptorYrelated protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-99
18. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid A-peptide across the bloodYbrain barrier and accumulation in the brain. Nat Med 2003;9:907-13
19. Bell RD, Sagare AP, Friednab AE, et al. Transport pathways for clearance of human Alzheimer's amyloid A-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2006;27:909-18
20. Deane R, Sagare A, Hamm K, et al. apoE isoformYspecific disruption of amyloid A peptide clearance from mouse brain. J Clin Invest 2008;118: 4002-13
21. Silverberg GD, Miller MC, Messier AA, et al. Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol 2010;69:98-108
22. Silverberg GD, Miller MC, Machan JT, et al. Amyloid and Tau accumulate in the brains of aged hydrocephalic rats. Brain Res 2010;1317:286-96
23. Yamada K, Hashimoto T, Yabuki C, et al. The low density lipoprotein receptorYrelated protein 1 mediates uptake of amyloid A peptides in an in vitro model of the blood-brain barrier cells. J Biol Chem 2008;283: 34554-62
24. Lam FC, Liu R, Lu P, et al. A-Amyloid efflux mediated by P-glycoprotein. J Neurochem 2001;76:1121-28
25. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier Increases amyloid-A deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285-90
26. Herz J, Strickland DK. LRP: A multifunctional scavenger and signaling receptor. J Clin Invest 2001;108:779-84
27. Kang DE, Pietrzik CU, Baum L, et al. Modulation of amyloid A-protein clearance and Alzheimer's disease susceptibility by the LDL receptorY related protein pathway. J Clin Invest 2000;106:1159-66
28. Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer's A-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogen 2002;12:535-41
29. National Institute of Aging. Alzheimer's Disease: Unraveling the Mystery. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; NIH Publication Number 2002;02-3782
30. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the aging human brain. Nature 2004;429:883-91
31. Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol 2008;3: 41-66
32. Geula C, Wu CK, Saroff D, et al. Aging renders the brain vulnerable to amyloid A-protein neurotoxicity. Nat Med 1998;4:827-31
33. Silverberg GD, Heit G, Huhn S, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 2001;57: 1763-66
34. Silverberg GD, Caralopoulos IN, Slone SL, et al. Amyloid and Tau accumulation precede CSF production decline in normal aging (abstract). CSF Res 2009;6(Suppl 1):S38.
35. Hincherick FR. Transmission electron microscopy. In: Prophet EB, Mills B, Arrington JB, Sobin LH, eds. Laboratory Methods in Histotechnology. Washington, DC: American Registry of Pathology 1992:257-63
36. Wu LC, D'Amelio F, Fox RA, et al. Light microscopic image analysis system to quantify immunoreactive terminal area apposed to nerve cells. J Neurosci Methods 1997;74:89-96
37. Stopa EG, Butala P, Salloway S, et al. Cerebral cortical arteriolar angiopathy, vascular A-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke 2008;39:814-21
38. Yousif S, Marie-Claire C, Roux F, et al. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain micro-vessel strategy. Brain Res 2007;1134:1-11
39. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006; 52:3-13
40. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid A-peptide. Nat Rev Mol Cell Biol 2007;8:101-12
41. Querfurth HW, LaFerla FM. Alzheimer's disease. N Eng J Med 2010; 362:329-44
42. Martel CL, Mackic JB, Matsubara E, et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid A. J Neurochem 1997;69:1995-2004
43. Monro OR, Mackic JB, Yamada S, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-A peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002;23:405-12
44. Arriagada P, Marzloff K, Hyman B. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992;42:1681-88
45. Davis D, Schmitt F, Wekstein D, Markesbery W. Alzheimer neuro-pathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376-88
46. Warrington JS, Greenblatt DJ, von Moltke LL. The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 2004;309:730-36
47. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994;269:9889-97
48. Herz J. The LDL receptor gene family: (Un)expected signal transducers in the brain. Neuron 2001;29:571-81
49. Howell BW, Herz J. The LDL receptor gene family: Signaling functions during development. Curr Opin Neurobiol 2001;11:74-81
50. Herz J, Marschang P. Coaxing the LDL receptor family into the fold. Cell 2003;112:289-92
51. Strickland DK, Ranganathan S. Diverse role of LDL receptorYrelated protein in the clearance of proteases and in signaling. J Thromb Haemost 2003;1:1663-70
52. Gonias SL, Wu L, Salicioni AM. Low density lipoprotein receptorY related protein: Regulation of the plasma membrane proteome. Thromb Haemost 2004;91:1056-64
53. Jaeger S, Pietrzik CU. Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 2008;5:15-25
54. Pascal T, Debacq-Chainiaux F, Chretien A, et al. Comparison of replica-tive senescence and stress-induced premature senescence combining differential display and low-density DNA arrays. FEBS Lett 2005;579:3651-59
55. Hong H, Liu LP, Liao JM, et al. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacol 2009;56:1054-59
56. Amos S, Mut M, diPierro CG, et al. Protein kinase C->Ymediated regulation of low-density lipoprotein receptor related protein and urokinase increases astrocytoma invasion. Cancer Res 2007;67:10241-51
57. Sima AV, Botez GM, Stancu CS, et al. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: Lipid loading, oxidative and inflammatory stress. J Cell Mol Med 2009;[E-pub ahead of print]
58. Gonzalez P, Alvarez R, Reguero JR, et al. Variation in the lipoprotein receptorYrelated protein, >2-macroglobulin and lipoprotein receptorY associated protein genes in relation to plasma lipid levels and risk of early myocardial infarction. Coron Artery Dis 2002;13:251-54
59. Jedrychowski MP, Gartner CA, Gygi SP, et al. Proteomic analysis of GLUT4 storage vesicles reveals LRP1 to be an important vesicle component and target of insulin signaling. J Biol Chem 2010;285:104-14
60. Liu Q, Zerbinatti CV, Zhang J, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007;56:66-78
61. Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end-products. J Biol Chem 1997;272:16498-506
62. Tohgi H, Utsugisawa K, Nagane Y, et al. Decrease with age in methyl-cytosines in the promoter region of receptor for advanced glycation end products (RAGE) gene in autopsy human cortex. Brain Res Mol Brain Res 1999;65:124-28
63. Chouliaras, L, Rutten BP, Kenis G, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010;90: 498-510
64. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994;77:491-502
65. Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-98
66. Pilorget A, Demeule M, Barakat S, et al. Regulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells. J Neurochem 2007;100:1203-10
67. Lim JC, Kania KD, Wijesuriya H, et al. Activation of A-catenin signalling by GSK-3 inhibition increases P-glycoprotein expression in brain endo-thelial cells. J Neurochem 2008;106:1855-65
68. Maeng HJ, Kim MH, Jin HE, et al. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: Evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 2007;35:1996-2005
69. Kooij G, van Horssen J, de Lange EC, et al. T lymphocytes impair P-glycoprotein function during neuroinflammation. J Autoimmun 2010; 34:416-25
70. Shi J, Perry G, Smith MA, Friedland RP. Vascular abnormalities: The insidious pathogenesis of Alzheimer's disease. Neurobiol Aging 2000; 21:357-61